Movement Alert｜Veradermics, Inc. Rises 11.38% in Pre-Market Trading, Ongoing VDPHL01 Clinical Progress and Cash Position Remain in Focus

Market Focus10-20

On October 20, Veradermics, Inc. rose 11.38% in Pre-Market Trading to $128.5307 per share, with turnover of $77.6 thousand.

The move appears tied to continued market focus on the company’s lead candidate VDPHL01 and its cash runway rather than a newly disclosed standalone corporate event.

Previously disclosed updates showed VDPHL01 met all primary and key secondary endpoints in a Phase 2/3 trial in male pattern hair loss. In a Phase 2 study in female pattern hair loss, most participants showed improvement after six months, while no treatment-related serious adverse events or cardiac adverse events were observed. On the financial side, the company last reported about $819.9 million in cash and marketable securities, which management said could fund operations through 2030. The company’s most recent earnings release for the June quarter also showed a net loss of $23.5 million, better than market expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment